Denali Therapeutics Inc (NASDAQ: DNLI) closed the day trading at $17.34 down -2.80% from the previous closing price of $17.84. On the day, 1080929 shares were traded.
Ratios:
For a better understanding of DNLI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.65 and its Current Ratio is at 13.65. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on December 13, 2023, initiated with a Buy rating and assigned the stock a target price of $32.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 01 ’24 when Krognes Steve E. sold 92,500 shares for $20.50 per share. The transaction valued at 1,896,250 led to the insider holds 47,341 shares of the business.
SATO VICKI L sold 1,666 shares of DNLI for $33,487 on Mar 15 ’24. The Director now owns 119,709 shares after completing the transaction at $20.10 per share. On Feb 15 ’24, another insider, SATO VICKI L, who serves as the Director of the company, sold 1,666 shares for $18.37 each. As a result, the insider received 30,604 and left with 121,375 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.30 while its Price-to-Book (P/B) ratio in mrq is 2.33.
Stock Price History:
Over the past 52 weeks, DNLI has reached a high of $33.31, while it has fallen to a 52-week low of $15.45.
Shares Statistics:
A total of 138.39M shares are outstanding, with a floating share count of 112.29M. Insiders hold about 19.31% of the company’s shares, while institutions hold 78.38% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from Dragonfly Energy Holdings Corp analysts. The consensus estimate for the next quarter is $17.34, with high estimates of $22.77 and low estimates of $37.48.
EPS for the following year is $Stocks, with Stocks analysts recommending between $ETF and $ETF.
